SCYNEXIS (FRA:135A) Cash Flow from Discontinued Operations : €0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

SCYNEXIS's cash flow from discontinued operations for the three months ended in Mar. 2025 was €0.00 Mil. It means SCYNEXIS received €0.00 Mil from the sale of part of business quarterly. SCYNEXIS's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

SCYNEXIS Cash Flow from Discontinued Operations Historical Data

The historical data trend for SCYNEXIS's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Cash Flow from Discontinued Operations Chart

SCYNEXIS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow from Discontinued Operations

Get a 7-Day Free Trial

SCYNEXIS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial															-	-	-	-	-

SCYNEXIS Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

SCYNEXIS Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (FRA:135A) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

SCYX:USA 0L49:UK 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

SCYNEXIS Headlines

No Headlines